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Abstract 
A large number of novel secondary sulfonamides based on the open saccharin scaffold were 
synthesized and evaluated as selective inhibitors of four different isoforms of human carbonic 
anhydrase (hCA I, II, IX and XII, EC 4.2.1.1). They were obtained by reductive ring opening of the 
newly synthesized N-alkylated saccharin derivatives and were shown to be inactive against the two 
cytosolic off-target hCA I and II (Kis > 10 µM). Interestingly, these compounds inhibited hCA IX in 
the low nanomolar range with Kis ranging between 20 and 298 nM and were extremely potent 
inhibitors of hCA XII isoenzyme (Kis ranging between 4.3 and 432 nM). Since hCA IX and XII are 
the cancer-related isoforms recently validated as drug targets, these results represent an important 
goal in the development of new anticancer candidates. Finally, a computational approach has been 
performed to better correlate the biological data to the binding mode of these inhibitors. 
 
Keywords: saccharin, selective carbonic anhydrase inhibitors, secondary sulfonamides, cancer-
related isoforms. 
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Introduction 
Carbonic anhydrases are a vast family of metalloenzymes (CAs, EC 4.2.1.1.) strongly involved in 
regulating cell homeostasis and intracellular pH by catalyzing the reversible hydration of carbonic 
dioxide to bicarbonate ions1. Fifteen human isoforms are discovered to date and can be 
differentiated on the basis of cellular localization, tissue distribution, catalytic activity and affinity 
to various inhibitors, thus representing validated therapeutic targets for the treatment of a wide 
range of diseases2. In particular, hCA IX and XII were identified as part of the complex machinery 
that primary and metastatic cancer cell lines use to compensate their dysregulated pH in poorly 
vascularized microenvironments, like the surroundings of solid tumours3. Targeting these cancer-
related isoforms has attracted a lot of attention, hence leading to the proliferation of literature on the 
subject and the development of structurally diverse inhibitors4-10. As a result of this superb effort, a 
potent hCA IX selective compound (SLC-0111) is currently in Phase I clinical trials for the 
treatment of solid metastatic tumours, consequently boosting the research for new suitable 
candidates11,12. 
Since the active site of CAs is characterized by the presence of a catalytic zinc ion hold in place by 
three histidine residues, one of the most successful approaches to design novel CAIs implies 
introducing a zinc binding group (ZBG) in the scaffold of potential inhibitors13. In fact, the most 
widely prescribed CAIs are characterized by the presence of a primary sulfonamide group, which 
efficiently engages the positively charged zinc ion upon deprotonation14. However, despite primary 
sulfonamides being preferred “zinc binding group”, they are usually associated with promiscuous 
profiles and lack of selectivity amongst the different isoforms. On the other side, secondary and 
tertiary sulfonamides have been lately reported in the literature as efficient and selective inhibitors 
of the cancer related hCA IX and XII isoforms 15-19, although their binding mode remains a subject 
of investigation20. In a recent publication, Ivanova et al. reported on the spontaneous ring opening 
of cyclic tertiary sulfonamides under basic (pH= 9) crystallization conditions21. Since hCAs do not 
possess any peptidase activity, they concluded that the base-catalyzed hydrolysis of the saccharin 
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isothiazolone ring happened before the inhibitor entered the active site, and proved their hypothesis 
by testing both open and closed analogues against a panel of hCAs (hCA I, hCA II, hCA IX and 
hCA XII). In particular, these open saccharin derivatives determined an increased inhibition of hCA 
IX, while retaining high activity against hCA II. Such promising results prompted us to investigate 
the effects of ring opening on our previously reported N-substituted saccharins as selective 
inhibitors of CA IX and XII7,22. In this paper, we used a reductive ring opening approach to induce 
the 5-membered isothiazolone ring of saccharin to collapse into its corresponding secondary 
sulfonamide and benzyl alcohol (Figure 1)23. The rationale behind this choice could be found in the 
opportunity of generating two new potential anchoring points for the zinc ion, while introducing 
several degrees of freedom to the bonds connecting the two hydrophobic phenyl substituents to the 
polar core of the molecule. In general, the newly synthesized compounds (1-21) proved to be as 
potent as or slightly less potent than parent inhibitors, while the selectivity for the cancer-related 
isoforms (hCA IX and XII) over the off-target hCA I and II improved dramatically. In fact, none of 
the reported compounds inhibited hCA I and II isoforms at concentrations lower than 10 µM, while 
Ki values spanned from 20 to 298 nM against hCA IX and from 4.3 to 382 nM against hCA XII. 
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Figure 1. Reductive ring opening approach to the synthesis of novel CAIs 
 
Chemistry 
Saccharin (1.0 eq.) was activated using freshly ground anhydrous potassium carbonate and the 
corresponding salt was then directly reacted with a proper electrophile (2 eq. of substituted benzyl 
halide or α-haloacetophenone) by stirring the reaction mixture in N,N-dimethylformamide at 80 °C 
overnight (Scheme 1). Following these optimized conditions (polar aprotic solvent), we strictly 
obtained only the more stable regioisomers (N-substituted saccharin derivatives) limiting the 
Chapman-Mumm thermal rearrangement to the less stable O-substituted counterparts24. N-
substituted saccharin derivatives were then subjected to reductive ring opening with an excess of 
NaBH4 in dry methanol at room temperature for 2-8 hrs to give the corresponding secondary 
sulfonamide compounds 1-21 in discrete yields following a previously reported procedure with 
slight modifications23. 
 
 
Scheme 1. Synthesis and structure of compounds 1-21. For R substituents see Table 1. 
 
Our choice of NaBH4 as a reducing agent depended on preliminary experiments which suggested 
that (i) the sulfone group was not affected by these mild reducing conditions leading to the carbonyl 
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group reduction to the alcohol level only with saccharin ring cleavage and that (ii) similar results 
were obtained for the preparation of o-hydroxymethyl-N-alkyl-benzamides starting from N-alkyl-
phthalimides25. 
In their IR spectra, we usually registered for the open saccharin derivatives new but expected 
signals for the OH and NH stretching at 3240 and 3470 cm-1, respectively, and the disappearance of 
the C=O stretching at 1735 cm-1. 
Biological evaluation 
All the synthesized compounds were tested to evaluate their inhibitory activity towards the 
ubiquitous off-target isoforms, hCA I and II, and the cancer-related ones, hCA IX and XII, by a 
stopped-flow, CO2 hydrase assay method and their CA inhibition data (Ki) are summarized in Table 
1. 
 
Table 1. Inhibitory activity of the open saccharin-based derivatives 1-21 and acetazolamide as a 
reference drug, against selected hCA isoforms by a stopped-flow CO2 hydrase assay. 
 
 
 
Compound R 
Ki (nM)
* 
hCA I hCA II hCA IX hCA XII 
1 2-CH3 >10000 >10000 218 4.6 
2 2-CF3 >10000 >10000 200 54 
3 2-NO2 >10000 >10000 104 383 
4 2-Br >10000 >10000 113 323 
5 3-CH3 >10000 >10000 223 4.3 
6 3-CF3 >10000 >10000 238 4.4 
7 3-NO2 >10000 >10000 176 382 
8 3-F >10000 >10000 268 247 
9 3-Br >10000 >10000 267 64 
10 4-CH3 >10000 >10000 120 5.7 
11 4-CF3 >10000 >10000 253 7.2 
12 4-CN >10000 >10000 126 57 
13 4-NO2 >10000 >10000 20 54 
14 4-F >10000 >10000 26 63 
15 4-Cl >10000 >10000 154 48 
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16 4-Br >10000 >10000 145 432 
17 2,6-diF >10000 >10000 296 45 
18 3,4-diCl >10000 >10000 298 40 
19 
-CH=CH-
CH=CH- 
>10000 >10000 294 345 
 
 
 
20 H >10000 >10000 224 64 
21 3-OCH3 >10000 >10000 31 355 
AAZ (acetazolamide) 250 12 25 6.0 
*Mean from 3 different assays (errors were in the range of ±5–10% of the reported values). 
 
Results and discussion 
The analysis of the biological data was accomplished comparing the open saccharin-based 
derivatives with their corresponding parent compounds in order to evaluate if the ring opening 
enhanced or reduced their biological activity. 
All the tested compounds had no affinity for the common off-target hCA I and II isoforms (Kis> 
10000 nM) compared to their corresponding parent drugs. Moreover, our molecules with a benzyl 
alcohol group, instead of a carboxylic acid21, abolished completely this inhibitory activity 
improving the biological profile of this scaffold. 
The inhibition profile of the open saccharin-based derivatives against the two tumor-related hCA IX 
and XII isoforms also displayed some important changes compared to parent drugs. Among the new 
open saccharin derivatives reported here, the best activity was obtained toward hCA XII isoform by 
compounds 1, 5, 6, 10 and 11, all provided of CH3 or CF3 groups. These molecules exhibited a 
slightly preference for hCA XII respect to hCA IX isoform, although the inhibition of the latter was 
also in the nanomolar range. Compound 5, containing a phenyl ring substituted with methyl group 
in meta position, had the highest inhibitory activity against hCA XII (Ki = 4.3 nM), but also 
compound 6, containing a meta trifluoromethyl substituent on phenyl ring, exhibited similar 
inhibitory activity (Ki = 4.4 nM). Comparable profile against hCA XII was observed for compounds 
10 (Ki = 5.7 nM) and 11 (Ki = 7.2 nM), which are para substituted regioisomers of 5 and 6, 
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respectively. Compound 1, which had a methyl group at ortho position of phenyl ring, showed 
similar inhibitory activity (Ki hCA XII = 4.7 nM) with respect to 5 and 6. Other compounds with 
strong selectivity between hCA IX and XII were 9 (Ki hCA IX = 267 nM, Ki hCA XII = 64 nM) 
with bromine in meta position of phenyl ring, 12 (Ki hCA IX = 126 nM, Ki hCA XII = 57 nM) 
containing a cyano group in para position, 15 (Ki hCA IX = 154 nM, Ki hCA XII = 48 nM) which 
had a para chloro-substituted phenyl ring, 17 and 18 with, respectively, 2,6-difluoro and 3,4-
dichloro-substituted phenyl rings. 
Conversely, some compounds displayed a good selectivity towards hCA IX isoform. Compounds 
with nitro substituents in ortho (3), meta (7) or para (13) position of the ring had potent inhibitory 
activity preferentially against this overexpressed isoform in the hypoxic tumoral niche. 
For compounds 20 (Ki hCA IX = 224 nM, Ki hCA XII = 64 nM) and 21 (Ki hCA IX = 31 nM, Ki 
hCA XII = 355 nM), the reaction with NaBH4 led to the further reduction of exocyclic carbonyl 
moiety. The presence of this additional group maintained the biological profile with a loss of 
inhibitory activity against hCA I and II and a preferential selectivity against the cancer-related 
isoforms. 
Collectively, these promising data showed that the reductive ring opening of the saccharin nucleus 
improved the hCA inhibitory activity with a better selectivity with respect to the off-target isoforms. 
From the above, we also observed that the inhibition profile was affected positively or negatively by 
the substitution pattern. 
Docking studies into the active site of hCA XII 
The open saccharin analogs (compounds 1–21) were endowed with inhibition values in the 
nanomolar range against hCA XII isoform (Ki values: 4.3–432 nM, Table 1, approximately 100 fold 
difference between lowest and highest Ki values). The interaction of compound 6 with the active 
site of hCA XII was shown as an example (Figure 2). Docking studies indicated that the 
hydroxymethyl group and one of the sulfonamide oxygen atoms could interact simultaneously with 
the Zn2+-ion, whereas the other sulfonamide oxygen atom was water accessible. This oxygen might 
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also form hydrogen bonds with the backbone of Thr199. The other polar substituents of the 
molecule were water accessible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Docked pose of compound 6 in the active site of hCA XII. Hydrogen bonds and 
interactions to the Zn2+-ion are depicted in red dashed lines. The Zn2+-ion is depicted as a turquoise 
sphere. The three zinc-binding Histidines (H94, H96 and H119) are depicted in light grey for clarity. 
 
Conclusion 
We proposed the design, synthesis, characterization and pharmacological evaluation in vitro of 
several new secondary sulfonamides based on the open saccharin scaffold as selective inhibitors of 
four different isoforms of human carbonic anhydrase. They were shown to be inactive against the 
two cytosolic off-target hCA I and II (Kis > 10 µM); conversely, all these compounds inhibited hCA 
IX and XII in the low nanomolar range with Kis ranging between 4.3 and 432 nM. The analysis of 
the Ki values showed as the substituent on phenyl moiety that gives the best outcomes relative to 
inhibition of hCA XII isoform are methyl and trifluoromethyl groups. The results were also 
rationalized by means of docking studies into the active site of hCA XII. Since these two cancer-
H119 
H94 
H96 
Q92 
K67 
H64 N62 
W5 
P202 
T200 
P201 
T199 
V121 
L198 
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related hCA isoforms were recently validated as drug targets, these results provided the 
development of new anticancer candidates. 
Experimental protocols 
General 
Solvents and reagents were used as supplied without further purification. Where mixtures of 
solvents are specified, the stated ratios are volume:volume. Acetazolamide was purchased by 
Sigma-Aldrich (Italy) and used in the biological assays without further purification. All synthesized 
compounds have been fully characterized by analytical and spectral data. Column chromatography 
was carried out using Sigma-Aldrich® silica gel (high purity grade, pore size 60 Å, 200-425 mesh 
particle size). Analytical thin-layer chromatography was carried out on Sigma-Aldrich® silica gel on 
TLA aluminum foils with fluorescent indicator. Visualization was carried out under UV irradiation 
(254 nm). 1H-NMR spectra were recorded on a Bruker AV400 (1H: 400 MHz, 13C: 101 MHz). 19F-
NMR spectra were recorded on a Bruker AVANCE 600 spectrometer (19F: 564.7 MHz). Chemical 
shifts are quoted in ppm, based on appearance rather than interpretation, and are referenced to the 
residual non deuterated solvent peak. In the case of 19F, chemical shifts are referenced to an external 
standard (CF3COOH, δ -76.55 ppm). Infra-red spectra were recorded on a Bruker Tensor 27 FTIR 
spectrometer equipped with an attenuated total reflectance attachment with internal calibration. 
Absorption maxima (νmax) are reported in wavenumbers (cm
-1). All melting points were measured 
on a Stuart® melting point apparatus SMP1 and are uncorrected. Temperatures are reported in °C. 
Where given, systematic compound names are those generated by ChemBioDraw Ultra® 12.0 
following IUPAC conventions. 
Procedures for the synthesis of the new open saccharin derivatives 
2-(Hydroxymethyl)-N-(2-methylbenzyl)benzenesulfonamide (1): (2-
methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 2 h the reaction was quenched with water and the aqueous phase 
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was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:4). The title compound was a white solid (52% yield); mp 64-
66 °C; IR νmax 3459 (ν O-H), 3237 (ν N-H), 3065 (ν Csp2-H), 1319 (νas S=O), 1167 (νs S=O), 712 (δ 
Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.25 (s, 3H, CH3), 2.77 (bs, 1H, OH, D2O exch.), 4.08 
(s, 2H, CH2), 5.01 (s, 2H, CH2), 5.43 (bs, 1H, NH, D2O exch.), 7.09-7.19 (m, 4H, CHAr), 7.47-7.61 
(m, 3H, CHAr), 8.01-8.04 (m, 1H, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 18.7 (CH3), 45.5 (CH2), 
64.2 (CH2), 126.2 (Ar), 128.2 (Ar), 128.5 (Ar), 128.9 (Ar), 129.6 (Ar), 129.9 (Ar), 130.5 (Ar), 
131.6 (Ar), 133.2 (Ar), 134.1 (Ar), 136.6 (Ar), 138.2 (Ar). 
2-(Hydroxymethyl)-N-(2-(trifluoromethyl)benzyl)benzenesulfonamide (2): (2-
trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL 
of anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 4 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product that was purified by column 
chromatography (EtOAc/n-hexane, 1:3). The title compound was a white solid (47% yield); mp 66-
68 °C; IR νmax 3446 (ν O-H), 3214 (ν N-H), 1310 (νas S=O), 1157 (νs S=O), 714 (δ Csp2-H) cm
-1; 
1H-NMR (400 MHz, CDCl3) δ 2.81 (t, 1H, J = 5.4 Hz, OH, D2O exch.), 4.17 (d, 2H, J = 6.0 Hz, 
CH2), 4.91 (s, 2H, CH2), 5.83 (m, 1H, NH, D2O exch.), 7.27 (t, 1H, J = 7.6 Hz, CHAr), 7.35-7.41 (m, 
3H, CHAr), 7.46-7.50 (m, 3H, CHAr), 7.89-7.91 (m, 1H, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 43.7 
(CH2), 63.9 (CH2), 124.2 (C-F, 
1JC-F =274.8 Hz, CF3), 125.9 (Ar), 126.0 (Ar), 127.9 (Ar), 128.6 
(Ar), 129.7 (Ar), 130.6 (Ar), 131.6 (Ar), 132.3 (Ar), 133.3 (Ar), 135.0 (Ar), 138.0 (Ar), 138.1 (Ar); 
19F-NMR (564.7 MHz, CDCl3) δ -56.89 (s, CF3). 
2-(Hydroxymethyl)-N-(2-nitrobenzyl)benzenesulfonamide (3): (2-
nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
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reaction monitored by TLC. After 6 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give the title compound as a light brown solid (37% 
yield); mp 103-105 °C; IR νmax 3498 (ν O-H), 3238 (ν N-H), 2973 (ν Csp3-H), 1522 (ν N-O), 1327 
(νas S=O), 1165 (νs S=O), 698 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, DMSO-d6) δ 4.34 (d, 2H, J = 
5.6 Hz, CH2), 4.88 (s, 2H, CH2), 5.45 (bs, 1H, OH, D2O exch.), 7.39 (t, 1H, J = 7.2 Hz, CHAr), 7.50 
(t, 1H, J = 7.6 Hz, CHAr), 7.60-7.68 (m, 3H, 3 x CHAr), 7.74-7.79 (m, 2H, 2 x CHAr), 7.96 (d, 1H, J 
= 8.4 Hz, CHAr), 8.29 (bs, 1H, NH, D2O exch.); 
13C-NMR (101 MHz, DMSO-d6) δ 43.4 (CH2), 60.0 
(CH2), 125.1 (Ar), 127.3 (Ar), 128.2 (Ar), 128.5 (Ar), 129.1 (Ar), 130.7 (Ar), 133.0 (Ar), 133.4 (Ar), 
134.1 (Ar), 137.0 (Ar), 141.6 (Ar), 148.1 (Ar). 
N-(2-Bromobenzyl)-2-(hydroxymethyl)benzenesulfonamide (4): (2-
bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 6 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 2:1). The title compound was a white solid (0.05 g, 11% yield); 
mp 162-164 °C; IR νmax 3273 (ν O-H and ν N-H), 2920 (ν Csp3-H), 1402 (νas S=O), 1065 (νs S=O), 
676 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 3.45 (bs, 1H, OH, D2O exch.), 4.14 (d, 2H, J = 
6.4 Hz, CH2), 4.93 (s, 2H, CH2), 6.18 (m, 1H, NH, D2O exch.), 7.03 (t, 1H, J = 7.6 Hz, CHAr), 7.15 
(t, 1H, J = 7.4 Hz, CHAr), 7.28 (d, 1H, J = 6.8 Hz, CHAr), 7.33-7.49 (m, 4H, CHAr), 7.87 (d, 1H, J = 
8.0 Hz, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 47.4 (CH2), 63.5 (CH2), 123.4 (Ar), 127.6 (Ar), 
128.3 (Ar), 129.4 (Ar), 129.6 (Ar), 130.3 (Ar), 131.3 (Ar), 132.7 (Ar), 133.1 (Ar), 135.6 (Ar), 137.8 
(Ar), 138.4 (Ar). 
2-(Hydroxymethyl)-N-(3-methylbenzyl)benzenesulfonamide (5): (3-
methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
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anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 7 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:4). The title compound was a white solid (51% yield); mp 79-
80 °C; IR νmax 3431 (ν O-H), 3161 (ν N-H), 2936 (ν Csp3-H), 1316 (νas S=O), 1152 (νs S=O), 694 (δ 
Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.27 (s, 3H, CH3), 2.80 (bs, 1H, OH, D2O exch.), 4.07 
(bs, 2H, CH2), 4.99 (s, 2H, CH2), 5.72 (bs, 1H, NH, D2O exch.), 6.96 (d, 2H, J = 7.6 Hz, CHAr), 
7.04 (d, 1H, J = 8.0 Hz, CHAr), 7.14 (t, 1H, J = 7.4 Hz, CHAr), 7.44-7.49 (m, 2H, CHAr), 7.55-7.59 
(m, 1H, CHAr), 7.98 (d, 1H, 7.8 Hz, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 21.3 (CH3), 47.5 (CH2), 
63.8 (CH2), 124.9 (Ar), 128.4 (Ar), 128.5 (Ar), 128.6 (Ar), 128.7 (Ar), 129.8 (Ar), 131.5 (Ar), 
133.1 (Ar), 136.1 (Ar), 138.1 (Ar), 138.2 (Ar), 138.3 (Ar). 
2-(Hydroxymethyl)-N-(3-(trifluoromethyl)benzyl)benzenesulfonamide (6): (3-
trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL 
of anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 8 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:3). The title compound was a white solid (71% yield); mp 76-
78 °C; IR νmax 3430 (ν O-H), 3278 (ν N-H), 1317 (νas S=O), 1160 (νs S=O), 700 (δ Csp2-H) cm
-1; 
1H-NMR (400 MHz, CDCl3) δ 2.98 (t, 1H, J = 4.8 Hz, OH, D2O exch.), 4.06 (d, 2H, J = 6.4 Hz, 
CH2), 4.91 (d, 2H, J = 4.0 Hz, CH2), 6.07 (m, 1H, NH, D2O exch.), 7.24-7.37 (m, 6H, CHAr), 7.42-
7.46 (m, 1H, CHAr), 7.82 (d, 1H, J = 7.6 Hz, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 46.9 (CH2), 
63.9 (CH2), 123.9 (C-F, 
1JC-F =273.4 Hz, CF3), 124.5 (Ar), 124.6 (Ar), 128.6 (Ar), 129.1 (Ar), 129.7 
(Ar), 130.7 (Ar), 131.3 (Ar), 131.7 (Ar), 133.3 (Ar), 137.4 (Ar), 137.8 (Ar), 138.0 (Ar); 19F-NMR 
(564.7 MHz, CDCl3) δ -60.09 (s, CF3). 
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2-(Hydroxymethyl)-N-(3-nitrobenzyl)benzenesulfonamide (7): (3-
nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. Excess of NaBH4 was added portionwise and the reaction 
monitored by TLC. After 6 h the reaction was quenched with water and the aqueous phase was 
extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium 
sulfate, and concentrated in vacuo to give a crude product that was purified by column 
chromatography (EtOAc/n-hexane, 2:1). The title compound was a white solid (37% yield); mp 
109-111 °C; IR νmax 3491 (ν O-H), 3164 (ν N-H), 2958 (ν Csp3-H), 1536 (ν N-O), 1326 (νas S=O), 
1162 (νs S=O), 695 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, DMSO-d6) δ 4.16 (s, 2H, CH2), 4.87 (s, 
2H, CH2), 5.47 (bs, 1H, OH, D2O exch.), 7.33-7.37 (m, 1H, CHAr), 7.51-7.60 (m, 2H, CHAr), 7.64 
(d, 1H, J = 7.6 Hz, CHAr), 7.73-7.75 (m, 2H, CHAr), 8.04 (s, 1H, CHAr), 8.06 (s, 1H, CHAr), 8.35 (bs, 
1H, NH, D2O exch.); 
13C-NMR (101 MHz, DMSO-d6) δ 45.4 (CH2), 59.9 (CH2), 122.5 (Ar), 122.6 
(Ar), 127.1 (Ar), 127.9 (Ar), 128.5 (Ar), 130.2 (Ar), 132.9 (Ar), 134.6 (Ar), 137.2 (Ar), 140.8 (Ar), 
141.5 (Ar), 148.1 (Ar). 
N-(3-Fluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (8): (3-
fluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 5 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:1). The title compound was a light yellow oil (67% yield); IR 
νmax 3492 (ν O-H), 3283 (ν N-H), 2895 (ν Csp3-H), 1318 (νas S=O), 1252 (ν Csp2-F), 1175 (νs S=O), 
689 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.84 (bs, 1H, OH, D2O exch.), 4.05 (s, 2H, 
CH2), 4.97 (s, 2H, CH2), 6.04 (bs, 1H, NH, D2O exch.), 6.85-6.94 (m, 3H, CHAr), 7.17-7.20 (m, 1H, 
CHAr), 7.39-7.55 (m, 3H, CHAr), 7.92 (d, 1H, J = 7.6 Hz, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 
46.6 (CH2), 63.6 (CH2), 114.6 (Ar-F, 
2JC-F = 21.1 Hz), 114.8 (Ar-F, 
2JC-F = 22.0 Hz), 123.4 (Ar-F, 
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long-rangeJC-F = 2.7 Hz), 128.5 (Ar), 129.7 (Ar), 130.1 (Ar-F, 
3JC-F = 8.2 Hz), 131.6 (Ar), 133.2 (Ar), 
137.9 (Ar), 138.1 (Ar), 139.0 (Ar-F, 3JC-F = 7.3 Hz), 162.7 (Ar-F, 
1JC-F = 247.45 Hz); 
19F-NMR 
(564.7 MHz, CDCl3) δ -110.03 (ddd, JF-H = 9.5 Hz, 8.6 Hz, 5.2 Hz, CF). 
N-(3-Bromobenzyl)-2-(hydroxymethyl)-benzenesulfonamide (9): (3-
bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 5 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:1). The title compound was a white solid (70% yield); mp 75-
76 °C; IR νmax 3454 (ν O-H), 3214 (ν N-H), 2955 (ν Csp3-H), 1319 (νas S=O), 1156 (νs S=O), 694 (δ 
Csp2-H) cm
-1; 1H-NMR (400 MHz, DMSO-d6) δ 4.00 (d, 2H, J = 6 Hz, CH2), 4.87 (d, 2H, J = 5.2 Hz, 
CH2), 5.42 (bs, 1H, OH, D2O exch.), 7.20 (bs, 2H, CHAr), 7.38 (bs, 3H, CHAr), 7.59-7.63 (m, 1H, 
CHAr), 7.75-7.78 (m, 2H, CHAr), 8.23 (bs, 1H, NH, D2O exch.); 
13C-NMR (101 MHz, DMSO-d6) δ 
45.6 (CH2), 59.9 (CH2), 122.0 (Ar), 127.0 (Ar), 127.2 (Ar), 127.9 (Ar), 128.5 (Ar), 130.4 (Ar), 
130.7 (Ar), 130.8 (Ar), 132.9 (Ar), 137.2 (Ar), 141.2 (Ar), 141.5 (Ar). 
2-(Hydroxymethyl)-N-(4-methylbenzyl)benzenesulfonamide (10): (4-
methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 6 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:4). The title compound was a white solid (56% yield); mp 
100-102 °C; IR νmax 3437 (ν O-H), 3130 (ν N-H), 2930 (ν Csp3-H), 1310 (νas S=O), 1151 (νs S=O), 
701 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.31 (s, 3H, CH3), 2.80 (bs, 1H, OH, D2O 
exch.), 4.07 (d, 2H, J = 5.2 Hz, CH2), 4.99 (s, 2H, CH2), 5.60 (bs, 1H, NH, D2O exch.), 7.06 (bs, 4H, 
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CHAr), 7.44-7.50 (m, 2H, CHAr), 7.55-7.60 (m, 1H, CHAr), 8.00 (d, 1H, 7.6 Hz, CHAr); 
13C-NMR 
(101 MHz, CDCl3) δ 21.1 (CH3), 47.3 (CH2), 63.8 (CH2), 127.9 (Ar), 128.5 (Ar), 129.3 (Ar), 129.9 
(Ar), 131.6 (Ar), 133.1 (Ar), 133.2 (Ar), 137.6 (Ar), 138.1 (Ar), 138.2 (Ar). 
2-(Hydroxymethyl)-N-(4-(trifluoromethyl)benzyl)benzenesulfonamide (11): (4-
trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL 
of anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 8 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:3). The title compound was a white solid (79% yield); mp 78-
80 °C; IR νmax 3417 (ν O-H), 3161 (ν N-H), 3065 (ν Csp2-H), 1321 (νas S=O), 1157 (νs S=O), 688 (δ 
Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 3.03 (bs, 1H, OH, D2O exch.), 4.15 (d, 2H, J = 6.4 Hz, 
CH2), 5.02 (d, 2H, J = 5.2 Hz CH2), 6.14 (t, 1H, J = 6.4 Hz, NH, D2O exch.), 7.32 (d, 2H, J = 8.0 Hz, 
CHAr), 7.40-7.49 (m, 4H, CHAr), 7.54-7.58 (m, 1H, CHAr), 7.91 (s, 1H, CHAr); 
13C-NMR (101 MHz, 
CDCl3) δ 46.9 (CH2), 63.9 (CH2), 124.0 (C-F, 
1JC-F= 273.1 Hz, CF3), 125.4 (Ar), 125.5 (Ar), 128.1 
(Ar), 128.6 (Ar), 129.7 (Ar), 129.8 (Ar), 130.1 (Ar), 131.7 (Ar), 133.3 (Ar), 137.8 (Ar), 138.0 (Ar), 
140.4 (Ar); 19F-NMR (564.7 MHz, CDCl3) δ -60.08 (s, CF3). 
N-(4-Cyanobenzyl)-2-(hydroxymethyl)benzenesulfonamide (12): (4-
cyanobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 8 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate and concentrated in vacuo to give a crude product, which was purified by column 
chromatography (EtOAc/n-hexane, 2:1). The title compound was a white solid (67% yield); mp 93-
95 °C; IR νmax 3481 (ν O-H), 3187 (ν N-H), 2949 (ν Csp3-H), 2235 CN, 1325 (νas S=O), 1156 (νs 
S=O), 703 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, DMSO-d6) δ 4.09 (s, 2H, CH2), 4.88 (s, 2H, CH2), 
Page 17 of 39
URL: http:/mc.manuscriptcentral.com/genz   EIC: Claudiu Supuran Email: claudiu.supuran@unifi.it
Journal Of Enzyme Inhibition And Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 17
5.46 (bs, 1H, OH, D2O exch.), 7.35-7.41 (m, 3H, CHAr), 7.59-7.62 (m, 1H, CHAr), 7.70-7.77 (m, 4H, 
CHAr), 8.33 (bs, 1H, NH, D2O exch.); 
13C-NMR (101 MHz, DMSO-d6) δ 45.9 (CH2), 59.9 (CH2), 
110.3 (Ar), 119.3 (CN), 127.2 (Ar), 127.9 (Ar), 128.5 (Ar), 128.7 (Ar), 132.6 (Ar), 132.9 (Ar), 
137.1 (Ar), 141.6 (Ar), 144.3 (Ar). 
2-(Hydroxymethyl)-N-(4-nitrobenzyl)benzenesulfonamide (13): (4-
nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 8 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product, which was purified by column 
chromatography (EtOAc/n-hexane, 1:1). The title compound was a yellow solid (57% yield); mp 
98-99 °C; IR νmax 3493 (ν O-H), 3243 (ν N-H), 1515 (ν N-O), 1318 (νas S=O), 1160 (νs S=O), 690 
(δ Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.74 (bs, 1H, OH, D2O exch.), 4.21 (bs, 2H, CH2), 
5.08 (s, 2H, CH2), 6.13 (bs, 1H, NH, D2O exch.), 7.40-7.59 (m, 5H, CHAr), 7.96-7.97 (m, 1H, CHAr), 
8.11-8.13 (m, 2H, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 46.7 (CH2), 64.3 (CH2), 123.7 (Ar), 128.5 
(Ar), 128.8 (Ar), 129.8 (Ar), 131.6 (Ar), 133.4 (Ar), 137.6 (Ar), 138.7 (Ar), 144.0 (Ar), 147.2 (Ar). 
N-(4-Fluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (14): (4-
fluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 8 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:3). The title compound was a light brown solid (79% yield); 
mp 99-100 °C; IR νmax 3439 (ν O-H), 3140 (ν N-H), 1312 (νas S=O), 1151 (νs S=O), 696 (δ Csp2-H) 
cm-1; 1H-NMR (400 MHz, CDCl3) δ 3.18 (bs, 1H, OH, D2O exch.), 4.04 (d, 2H, J = 6.4 Hz, CH2), 
4.98 (s, 2H, CH2), 6.00 (bs, 1H, NH, D2O exch.), 6.88-6.93 (m, 2H, CHAr), 7.12-7.15 (m, 2H, CHAr), 
Page 18 of 39
URL: http:/mc.manuscriptcentral.com/genz   EIC: Claudiu Supuran Email: claudiu.supuran@unifi.it
Journal Of Enzyme Inhibition And Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 18
7.41-7.57 (m, 3H, CHAr), 7.93 (d, 1H, J = 8.0 Hz, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 46.7 (CH2), 
63.7 (CH2), 115.4 (Ar-F, 
2JC-F =21.2 Hz), 128.5 (Ar), 129.6 (Ar), 129.7 (Ar), 131.6 (Ar), 132.0 (Ar), 
132.1 (Ar), 133.2 (Ar), 138.0 (Ar), 138.1 (Ar), 135.4 (Ar-F, 1JC-F =247.3 Hz); 
19F-NMR (564.7 
MHz, CDCl3) δ -111.71 (tt, JF-H = 8.7 Hz (ortho), 5.3 Hz (meta), CF). 
N-(4-Chlorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (15): (4-
chlorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 7 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:1). The title compound was a white solid (70% yield); mp 
103-105 °C; IR νmax 3458 (ν O-H), 3236 (ν N-H), 2876 (ν Csp3-H), 1314 (νas S=O), 1152 (νs S=O), 
690 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.90 (bs, 1H, OH, D2O exch.), 4.06 (d, 2H, J = 
6.0 Hz, CH2), 5.01 (s, 2H, CH2), 5.88 (bs, 1H, NH, D2O exch.), 7.11 (d, 2H, J = 8.4 Hz, CHAr), 7.21 
(d, 2H, J = 8.4 Hz, CHAr), 7.43-7.49 (m, 2H, CHAr), 7.56-7.60 (m, 1H, CHAr), 7.95 (d, 1H, J = 7.6 
Hz, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 46.8 (CH2), 63.9 (CH2), 128.6 (Ar), 128.7 (Ar), 129.3 
(Ar), 129.8 (Ar), 131.6 (Ar), 133.2 (Ar), 133.7 (Ar), 134.8 (Ar), 137.9 (Ar), 138.1 (Ar). 
N-(4-bromobenzyl)-2-(hydroxymethyl)benzenesulfonamide (16): (4-
bromobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 7 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:2). The title compound was a white solid (53% yield); mp 
124-125 °C; IR νmax 3461 (ν O-H), 3234 (ν N-H), 3064 (ν Csp2-H), 1314 (νas S=O), 1152 (νs S=O), 
690 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.71 (bs, 1H, OH, D2O exch.), 4.06 (bs, 2H, 
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CH2), 5.03 (s, 2H, CH2), 5.78 (bs, 1H, NH, D2O exch.), 7.06-7.08 (m, 2H, CHAr), 7.37-7.59 (m, 5H, 
CHAr), 7.96-7.97 (m, 1H, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 46.9 (CH2), 64.1 (CH2), 121.9 (Ar), 
128.6 (Ar), 129.6 (Ar), 129.8 (Ar), 131.7 (Ar), 133.2 (Ar), 137.9 (Ar), 138.3 (Ar). 
N-(2,6-Difluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (17): (2,6-
difluorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 7 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:1). The title compound was a white solid (67% yield); mp 
128-130 °C; IR νmax 3495 (ν O-H), 3159 (ν N-H), 2958 (ν Csp3-H), 1320 (νas S=O), 1159 (νs S=O), 
693 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.72 (bs, 1H, OH, D2O exch.), 4.23 (s, 2H, 
CH2), 4.89 (bs, 2H, CH2), 6.04 (bs, 1H, NH, D2O exch.), 6.79-6.73 (m, 2H, CHAr), 7.10-7.14 (m, 
1H, CHAr), 7.26 (s, 1H, CHAr), 7.33-7.48 (m, 2H, CHAr), 7.92-7.94 (m, 1H, CHAr); 
13C-NMR (101 
MHz, CDCl3) δ 35.1 (CH2), 63.6 (CH2), 111.2 (Ar-F, 
2JC-F = 24.8 Hz), 128.3 (Ar), 129.7 (Ar), 129.9 
(Ar), 130.0 (Ar), 130.1 (Ar), 131.2 (Ar), 133.1 (Ar), 137.8 (Ar), 138.2 (Ar), 161.2 (Ar-F, 1JC-F = 
246.9 Hz); 19F-NMR (564.7 MHz, CDCl3) δ -112.08 (t, JF-H = 6.9 Hz, CF). 
N-(3,4-Dichlorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (18): (3,4-
chlorobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 7 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 2:1). The title compound was a light brown solid (81% yield); 
mp 83-84 °C; IR νmax 3463 (ν O-H), 3192 (ν N-H), 2947 (ν Csp3-H), 1319 (νas S=O), 1158 (νs S=O), 
690 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.88 (bs, 1H, OH, D2O exch.), 3.96 (d, 2H, J = 
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6.4 Hz, CH2), 4.93 (bs, 2H, CH2), 6.00 (t, 1H, J = 6.0 Hz NH, D2O exch.), 6.94-6.96 (bs, 1H, CHAr), 
7.17-7.22 (m, 2H, CHAr), 7.33-7.39 (m, 2H, CHAr), 7.46-7.48 (m, 1H, CHAr), 7.83 (d, 1H, J = 7.6 
Hz, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 46.3 (CH2), 64.0 (CH2), 127.2 (Ar), 128.6 (Ar), 129.7 
(Ar), 129.8 (Ar), 130.5 (Ar), 131.7 (Ar), 131.8 (Ar), 132.6 (Ar), 133.3 (Ar), 136.7 (Ar), 137.7 (Ar), 
138.1 (Ar). 
2-(Hydroxymethyl)-N-(naphthalen-1-ylmethyl)benzenesulfonamide (19): 2-(naphthalen-1-
ylmethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous 
methanol at room temperature. An excess of NaBH4 was added portionwise and the reaction 
monitored by TLC. After 6 h the reaction was quenched with water and the aqueous phase was 
extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium 
sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 1:1). The title compound was a white solid (57% yield); mp 80-
81 °C; IR νmax 3517 (ν O-H), 3347 (ν N-H), 3061 (ν Csp2-H), 1318 (νas S=O), 1157 (νs S=O), 690 (δ 
Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.68 (bs, 1H, OH, D2O exch.), 4.51 (s, 2H, CH2), 4.91 
(s, 2H, CH2), 5.69 (bs, 1H, NH, D2O exch.), 7.29-7.55 (m, 7H, CHAr), 7.74-7.86 (m, 3H, CHAr), 
8.05 (s, 1H, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 45.6 (CH2), 63.7 (CH2), 123.2 (Ar), 125.2 (Ar), 
126.0 (Ar), 126.6 (Ar), 127.0 (Ar), 128.4 (Ar), 128.7 (Ar), 129.0 (Ar), 130.0 (Ar), 131.1 (Ar), 131.4 
(Ar), 131.5 (Ar), 133.2 (Ar), 133.7 (Ar), 137.6 (Ar), 138.3 (Ar). 
N-(2-Hydroxy-2-phenylethyl)-2-(hydroxymethyl)benzenesulfonamide (20): 2-(2-oxo-2-
phenylethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of 
anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the 
reaction monitored by TLC. After 8 h the reaction was quenched with water and the aqueous phase 
was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over 
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column 
chromatography (EtOAc/n-hexane, 2:1). The title compound was a light yellow oil (49% yield); IR 
νmax 3291 (ν O-H and ν N-H), 2923 (ν Csp3-H), 1316 (νas S=O), 1153 (νs S=O), 696 (δ Csp2-H) cm
-1; 
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1H-NMR (400 MHz, CDCl3) δ 2.94 (bs, 1H, CH2), 3.15 (bs, 1H, CH2), 3.42 (bs, 1H, OH, D2O 
exch.), 4.56-4.64 (m, 2H, CH2), 4.91-5.03 (m, 1H, CH), 5.28 (bs, 1H, OH, D2O exch.), 6.57 (bs, 1H, 
NH, D2O exch.), 7.13-7.20 (m, 5H, CHAr), 7.38-7.47 (m, 3H, CHAr), 7.91 (d, 1H, J = 6.4 Hz, CHAr); 
13C NMR (101 MHz, CDCl3) δ 50.4 (CH2), 62.7 (CH2), 72.4 (CH), 125.8 (Ar), 127.9 (Ar), 128.2 
(Ar), 128.5 (Ar), 129.5 (Ar), 131.3 (Ar), 133.3 (Ar), 137.3 (Ar), 138.6 (Ar), 140.8 (Ar). 
N-(2-Hydroxy-2-(3-methoxyphenyl)ethyl)-2-(hydroxymethyl)benzenesulfonamide (21): 2-(2-
hydroxy-2-(3-methoxyphenyl)ethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was 
suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH4 was added 
portionwise and the reaction monitored by TLC. After 8 h the reaction was quenched with water 
and the aqueous phase was extracted with dichloromethane (3 x 30 mL). The organic layers were 
reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was 
purified by column chromatography (EtOAc/n-hexane, 1:2). The title compound was a yellow oil 
(88% yield); IR νmax 3477 (ν O-H), 3295 (ν N-H), 2935 (ν Csp3-H), 1317 (νas S=O), 1160 (νs S=O), 
697 (δ Csp2-H) cm
-1; 1H-NMR (400 MHz, CDCl3) δ 2.89-2.95 (m, 1H, CH2), 3.13-3.17 (m, 1H, 
CH2), 3.64 (s, 3H, OCH3), 4.41 (bs, 2H, CH2), 4.58 (bs, 1H, OH), 4.87-4.91 (m, 1H, CH), 4.97 (bs, 
1H, OH, D2O exch.), 6.48 (bs, 1H, NH, D2O exch.), 6.67-6.71 (m, 3H, CHAr), 7.07-7.11 (m, 1H, 
CHAr), 7.32-7.47 (m, 3H, CHAr), 7.87 (d, 1H, J = 7.6 Hz, CHAr); 
13C-NMR (101 MHz, CDCl3) δ 
50.4 (CH2), 55.1 (OCH3), 60.6 (CH2), 72.2 (CH), 111.4, (Ar), 113.3 (Ar), 118.1 (Ar), 128.2 (Ar), 
129.5 (Ar), 129.6 (Ar), 131.2 (Ar), 133.2 (Ar), 137.3 (Ar), 138.6 (Ar), 142.5 (Ar), 159.5 (ArO). 
Enzyme inhibition assays 
An Applied Photophysics stopped-flow instrument has been used for assaying the CA-catalyzed 
CO2 hydration activity. Phenol red (0.2 mM) has been used as indicator, working at the absorbance 
maximum of 557 nm, with 20 mM Hepes (pH 7.5, for α-CAs) as buffer, and 20 mM NaClO4 (for 
maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO2 
hydration reaction for a period of 10-100 s. The CO2 concentrations ranged from 1.7 to 17 mM for 
the determination of the kinetic parameters and inhibition constants. For each inhibitor at least six 
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traces of the initial 5-10% of the reaction have been used for determining the initial velocity. The 
uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. 
Stock solutions of each inhibitor (1 µM) were prepared in distilled-deionized water and dilutions up 
to 0.1 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were 
preincubated together for 15 min at room temperature prior to assay, in order to allow for the 
formation of the E-I complex or for the eventual active site mediated hydrolysis of the inhibitor. 
The inhibition constants were obtained by non-linear least-squares methods using PRISM 3 and the 
Cheng-Prusoff equation, and represent the average from at least three different determinations. All 
recombinant CA isoforms were obtained in-house as previously reported26,27. 
Molecular modelling studies 
Preparation of saccharin-based structures 
The saccharin-based analogs 1-21 were prepared in 3D with the MOE software package 
(v2013.08.02, Chemical Computing Group Inc., Montreal, Canada) as previously reported28. All 
possible structural isomers of compounds were constructed. Strong acids were deprotonated and 
strong bases were protonated. Finally, the ligands were energy minimized using a steepest-descent 
protocol (MMFF94x force field). 
Preparation of hCA crystal structures for docking studies 
The structures of hCA I (PDB: 3LXE, 1.90 Å), hCA II (PDB: 4E3D, 1.60 Å), hCA IX (PDB: 3IAI, 
2.20 Å) and hCA XII (PDB: 1JD0, 1.50 Å) were obtained from the protein databank (PDB). The 
protein atoms, the active site zinc ions and the zinc-bound water molecule of hCA II were retained 
and all other atoms were omitted. The remaining structure was protonated using the MOE software 
package and subsequently the obtained structure was energy-minimized (AMBER99 force field). 
Finally, the obtained protein models were superposed on the hCA I structure using the backbone 
Cα-atoms. The zinc-bound water molecule of hCA II coordinated well to the zinc ions of the other 
hCAs. 
Docking studies 
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The GOLD Suite software package (v5.2, CCDC, Cambridge, UK) and the GoldScore scoring 
function were used to dock the derivatives into the hCA structures with and without the zinc-bound 
water molecule (25 dockings per ligand). The binding pocket was defined as all residues within 13 
Å of a centroid (x: -17.071, y: 35.081, 43.681; corresponding approximately to the position of the 
thiadiazole ring of acetazolamide in the 1JD0 structure). 
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Reviewer: 1 
Comments to the Author 
The manuscript of Melissa D’Ascenzio et al. reports on the synthesis, characterization and in vitro 
kinetic assay of opened saccharin compounds bearing the secondary sulfonamide moieties. The 
paper is well written, the scientific work well conducted and the data presented will be of particular 
importance in the field. Only minor suggestion are advised: 
1) Introduction: in the first sentence please change carbon anhydride into carbon dioxide 
It was changed. 
 
2) Try to avoid spoken popular english sentences such as at pag 4 "...inhibitor got in the active 
site.." 
The text has been checked and revised when necessary. 
 
3) in the chemistry experimental section please properly refer to the "organics" as the "organic 
layers" 
It was changed accordingly. 
 
4) I guess the hexane the authors used is n-hexane 
It was changed. 
 
 
Reviewer: 2 
Comments to the Author 
Several structurally new saccharin derivatives containing sulfonamide groups have been 
synthesized and tested against a panel of human carbonic anhydrases. The compounds showed 
selectivity against the tumor-associated isozymes IX and XII over the widely distributed human 
isozymes I and II. Finally, docked poses have been suggested for the compounds. There are only 
minor comments on the manuscript. 
*) The NMR data of compounds 12, 18 and 20 should be checked again. 
NMR signals have been revised. 
 
*) The quality of figure 2 should be improved. 
Figure 2 has been improved. 
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Figure S1. 
1
H NMR spectrum of compound 2. 
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Figure S2. 
13
C NMR spectrum of compound 2. 
 
 
 
Figure S3. 
19
F NMR spectrum of compound 2. 
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Figure S4. 
1
H NMR spectrum of compound 6. 
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Figure S5. 
13
C NMR spectrum of compound 6. 
 
 
Figure S6. 
19
F NMR spectrum of compound 6. 
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Figure S7. 
19
F NMR spectrum of compound 8. 
 
 
Figure S8. 
1
H NMR spectrum of compound 11. 
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Figure S9. 
13
C NMR spectrum of compound 11. 
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Figure S10. 
19
F NMR spectrum of compound 11. 
 
 
 
Figure S11. 
19
F NMR spectrum of compound 14. 
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Figure S12. 
19
F NMR spectrum of compound 17. 
 
 
 
Figure S13. 
1
H NMR spectrum of compound 18. 
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